French firm's coronavirus vaccine gets approval for use in the UK

A Covid vaccine developed by French firm Valneva was granted regulatory approval on Thursday by the British Medicines and Healthcare products Regulatory Agency (MHRA).

Topics
Coronavirus Vaccine | Coronavirus | UK

IANS  |  London 

vaccine
UK approves French firm's covid vaccine

A Covid vaccine developed by French firm Valneva was granted regulatory approval on Thursday by the British Medicines and Healthcare products Regulatory Agency (MHRA).

The Valneva jab is the first whole-virus inactivated Covid vaccine to gain regulatory approval in the UK, Xinhua news agency reported.

The vaccine is approved for use in people aged between 18-50, with the first and second doses to be taken at least 28 days apart.

The British independent medicines regulator is the first in the world to approve the Valneva product, MHRA said in a statement. It is also the sixth vaccine to be granted an MHRA authorisation.

The reported 238,938 Covid cases and 1,984 deaths in the past seven days. The caseload has reached 21,747,638, with total deaths of 171,396, official figures on Thursday showed.

More than 92 per cent of people aged 12 and above in Britain have received at least one shot of Covid vaccine and more than 86 per cent have received two shots and more than 67 per cent have received a booster jab.

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Fri, April 15 2022. 13:01 IST
RECOMMENDED FOR YOU